What caused the BIT.AX stock spike on 31 Jan 2026?

The spike followed heavy trading with **12,999,697** shares changing hands. No single confirmed corporate release was cited; investors appear to be reacting to trial speculation and the upcoming earnings/announcement window on **26 Feb 2026**.

What are the valuation metrics for BIT.AX stock?

Biotron shows **EPS -A$0.01**, **PE -0.40**, **Price/Book 7.95** and **Price/Sales 3.66**. The company is loss-making with limited revenue, placing it in speculative biotech valuation territory.

What is Meyka AI’s view and forecast for BIT.AX stock?

Meyka AI rates BIT.AX **60.77 (Grade B — HOLD)**. Meyka AI's forecast model projects **A$0.008** in 12 months, implying **100.00%** upside from **A$0.004**. Forecasts are projections and not guarantees.

How should traders manage risk for BIT.AX stock moves?

Use small position sizes, set clear stop-loss levels near **A$0.002–A$0.003**, and watch intraday volume for confirmation. High relative volume today suggests rapid moves both directions for this ASX small-cap.

AU Stocks

Biotron (BIT.AX, ASX) up 33.33% intraday 31 Jan 2026: volume surge merits attention

ByDanny Kontos January 31, 2026January 31, 2026

The BIT.AX stock jump is led by a 33.33% intraday rise to A$0.004 on 31 Jan 2026, driven by a volume spike to 12,999,697 shares. Traders flagged the move in an otherwise quiet news flow for Biotron Limited (BIT.AX) on the ASX. This article breaks down the intraday price action, why volume matters for small-cap biotech, the key financial metrics, and what our models say about short-term risk and a possible one-year target.